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We evaluated the risk of developing melanoma over time in members of 23 melanoma-prone families. All 23 families had
dysplastic nevi as well as melanoma. Forty-seven melanomas occurred prospectively, all in family members with dysplastic
nevi. The prospective melanomas were markedly thinner than the melanomas diagnosed prior to or at the time of the
subject’s entry into the study. The cumulative risk of melanoma by age 50 years among people with dysplastic nevi was
48.9±4.2%. Overall, the relative risk of a prospective melanoma among family members with previous melanoma was
229 (95% confidence interval 110–422). The risk varied by time interval and was 362 in the first 5 years, decreasing to 120 after
5 years. The risk of developing melanoma was 85 times increased (95% confidence interval 41–156) in family members with
dysplastic nevi and also declined over time in this group. There was no significant excess of cancers other than melanoma.
Close surveillance of these high-risk families has led to diagnosis of melanoma at an earlier developmental stage, which
should result in a decrease in mortality over time. J Invest Dermatol 100:350S–355S, 1993
In 1978, Wallace Clark and Mark Greene reported the clinical [1] and
histologic [2] features of a newly recognized precursor of melanoma.
At that time, they provisionally named these precursors ‘‘B-K moles.’’
Subsequently, the name of these distinctive lesions was changed to
dysplastic nevi to reflect the histologic characteristics of these nevi [3].
Although the nevi were first described in the setting of melanoma-
prone families, it became apparent that these nevi were important
precursors of melanoma outside the family setting [4–9]. Subsequent
studies have also demonstrated that 2–18% of surveyed populations
without melanoma have dysplastic nevi [5–11].
Much of the focus of the continuing collaboration between the
National Cancer Institute and the University of Pennsylvania
Pigmented Lesion Study Group has been on genetic studies in these
melanoma-prone families. In these families, the markedly increased
risk of melanoma is restricted to people with dysplastic nevi [12].
Dysplastic nevi and melanoma appear to be pleiotropic effects of a
single autosomal dominant gene that may be located on chromosome
band 1p36 [13,14]. Although this linkage finding has not yet been
confirmed by other groups, there have been major discrepancies in the
diagnostic criteria used for dysplastic nevi and melanoma [15,16].
These differences prohibit comparison of the data.
In addition to the genetic studies, the risk of melanoma and other
cancers in these families has been evaluated. Family members with
prior melanoma have been estimated to have a 500 times increased
risk of developing a subsequent melanoma, compared with general
population rates [12]. Family members with dysplastic nevi were
estimated to have a 148 times increased risk of melanoma [12]. The
risk of cancers other than melanoma was not significantly increased,
either in all bloodline relatives or in family members with dysplastic
nevi or melanoma [17]. Since the last report of these risks, an
additional nine families have been accrued and evaluated, and longer
follow-up is available for the original 14 families.
METHODS
Patient Population Families with at least two cases of melanoma were identified
from the registry of cancer-prone families maintained by the Family Studies
Section of the National Cancer Institute. The ascertainment of these families
varies; some are referred by physicians or other health care professionals, and
some are self-referred. Originally, 14 families with at least two living relatives
having documented cutaneous melanoma were identified and studied [12,18].
Additional families with two or more living relatives with documented
cutaneous melanoma have continued to be accrued. Currently, 23 such
families have participated in this study after giving informed consent. The
families resided in various regions of the United States.
Prior to clinical evaluation, the diagnoses of melanoma were confirmed by
histologic review of the primary melanoma when possible or metastatic disease
if the primary was not available. If histologic material was no longer available,
the diagnosis of melanoma was documented by review of local pathology
reports, medical records, or death certificates. Only confirmed invasive
cutaneous melanomas were counted as melanoma. Lesions that had histologic
characteristics of melanoma but were not invasive (melanoma in situ) were
designated as borderline lesions. When possible, the presence or absence of a
precursor lesion was noted during the histologic review. After documentation of
melanoma in at least two family members, each family was clinically evaluated.
All subjects with melanoma who were available for study and their willing first-
and second-degree relatives were asked to participate.
The initial clinical evaluation included a routine medical history,
phlebotomy to obtain lymphocytes for genetic studies, and complete skin
examination. For each family member, a structured clinical examination form
was completed that records the type, distribution, and number (categorical) of
nevi; the extent of freckling; the extent of solar damage; hair, eye, and skin
color; and other skin findings (cafe au lait, congenital nevi, nevus spilus, etc.).
After the skin examination, each participant was photographed. Both routine
overviews of each region and closeups of selected characteristic nevi were
taken. At the end of the clinical evaluation, each family member was counseled
with regard to his or her risk for melanoma and was given skin-care guidelines.
After the initial visit, all members received a letter reinforcing what they were
told and including information from any histologic review of their nevi. If nevi
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suspicious for melanoma were found during the clinical evaluation, then
biopsies were subsequently performed. In the initial phase of the study, when
the first 14 families were examined, all study participants were asked to undergo
biopsy of their most atypical nevus, even if it was not thought to be a dysplastic
nevus. Participants thought to have dysplastic nevi were asked to undergo
biopsy of their two most atypical lesions clinically characteristic of dysplastic
nevi. At the present time, biopsies of nevi are only done when clinically
indicated. When possible, all pigmented lesions removed prior to enrollment in
the study and all biopsies performed subsequently are histologically reviewed.
After enrollment in the study, family members are contacted routinely. In
addition, skin-care guidelines are reinforced, and any further information about
melanoma risk reduction is sent to family members.
Clinical and histologic criteria for the diagnosis of dysplastic nevi have been
previously described [1,2,12,18–20]. Briefly, the clinical characteristics of a
dysplastic nevus include a macular component, irregular and indistinct borders,
variable color (including tan, brown, dark brown, and pink), and a diameter
greater than 5mm. Although dysplastic nevi occur most commonly on sun-
exposed areas, they also are found in areas unusual for common acquired nevi,
such as the scalp and buttocks, and, in women, the breasts. The histologic
findings include basilar melanocytic hyperplasia of large epithelioid melano-
cytes with variable nuclear atypia, a patchy lym-phocytic infiltrate, concentric
eosinophilic fibroplasia, and lamellar fibroplasia. Participants were classified as
having dysplastic nevi if they had clinical and histologic evidence of dysplastic
nevi. If a person died prior to onset of the study and had histologic evidence of
dysplastic nevi, he or she was considered as having dysplastic nevi. In the newer
families, because of the change in the biopsy procedures, not every person with
clinical dysplastic nevi has had a nevus biopsy. Those family members with
florid clinical dysplastic nevi were considered affected for these analyses. Two
groups were considered indeterminant because of age: the young (under age 20)
and those over age 60, unless they had clinical and histologic verification of
dysplastic nevi.
Statistical Methods In each family, the first two melanoma cases that identified
the family as a melanoma-prone family were designated as the index cases. For
estimates of prospective risk and risks of subsequent primary melanomas, these
index cases were excluded. To estimate the prospective risk of melanoma,
person-years of observation were compiled according to gender, age, and
calendar period from the date of first clinical examination until development of
melanoma, death, or October 1, 1991, with the use of the computer program of
Monson [21]. For the estimates of all prospective cancer risks, person-years
were cumulated similarly from the date of first clinical examination to
development of cancer, death, or October 1,1991. The person-years for the
risks of subsequent melanomas began at the time of diagnosis of the first,
second, third, or fourth melanoma, even if they were prior to the first clinical
examination, and ended October 1, 1991, the date of death, or the date of
diagnosis of the second, third, fourth, or fifth melanoma, respectively. The
prospective portion of these risks for subsequent melanomas excluded
synchronous lesions and only included melanomas diagnosed after the initial
clinical exam. Tumor incidence rates from the Connecticut Tumor Registry
specific for gender, age, and calendar year were multiplied by the accumulated
person-years to estimate the number of cases of melanoma or other cancers
expected had this group experienced the same risk of cancers as the general
population. The Connecticut Tumor Registry rates were used because of the
time periods involved and the comparison of the risk of second melanomas
[22]. These Connecticut-based relative risks were also compared with similar
estimates generated with the Surveillance, Epidemiology, and End Results
incidence rates [23]. Statistical methods for risk estimation were based on the
assumption that the observed melanomas and other cancers followed a Poisson
distribution. Tests of significance and confidence intervals for the relative risk
(observed to expected cases) were calculated with the use of exact Poisson
probabilities [24]. To obtain the excess risk per 10,000 patients/year, the
expected number of cases was subtracted for the number observed. The
difference was divided by person-years of observation and then multiplied by
104. Tests for trend and homogeneity were performed as described previously
by Breslow and colleagues [24]. Cumulative probability of developing
melanoma by age was calculated with the use of the actuarial method of
Kaplan and Meier [25].
RESULTS
Four-hundred-seventy members of the families have been system-
atically examined, and some clinical information is available for an
additional 26 members with melanoma who died before their families
were enrolled in the study. All 23 kindreds had dysplastic nevi as well
as melanoma. One-hundred-six of the participants were spouses, four
had dysplastic nevi, and one had a previous melanoma. Of the
bloodline relatives, 146 were without dysplastic nevi, 50 had an
indeterminate status, and 168 had dysplastic nevi. Four participants
with melanoma clinically affected with dysplastic nevi died prior to
biopsy of a representative nevus; four deceased participants with
melanoma had evidence of a precursor dysplastic nevus in their
primary lesion; and 21 participants with melanoma were indetermi-
nate because they were dead and had insufficient data available. Two
of these had clinical histories of prominent nevi.
In these 23 families, 199 invasive melanomas have occurred
among 105 family members. Forty-seven of these have developed
since the family member entered the study (prospective). All of the
prospective melanomas have developed in family members with
dysplastic nevi, and all but one of the prospective lesions have been
histologically reviewed. The primary lesion of 137 of the 152
melanomas that occurred prior to or at the time of initial entry into
the study have been histologically reviewed. The characteristics of the
lesions appear in Table I. Of the remaining 15 melanomas, all of
which occurred long before the study was initiated, eight were
documented by histologic review of metastatic lesions, and seven
were verified by medical records. Superficial spreading melanoma is
the predominant subtype. The percentage of lesions with histologic
evidence of dysplastic or other nevi is similar in the prospective lesions
to those diagnosed at an earlier time period. The lesional thickness and
level, however, have decreased over time, with 86% of the
prospective melanomas being less than 0.76mm thick, and 76%
being Clark level II or less. The thicker lesions occurred in people who
had not followed the recommendations about routine skin self-
examination and physician examinations. The average age at first
melanoma was 35 years (range 10–76).
In addition to the invasive melanomas, 58 borderline lesions have
occurred among 31 participants with dysplastic nevi. Eighteen of these
family members have also had invasive melanoma, but 13 have not
yet developed invasive lesions. Twenty-eight of the borderline lesions
occurred prior to entry in the study (seven prevalent at the initial
examination), and 30 developed prospectively among 19 individuals
(12 with prior melanoma; seven without invasive melanoma). The
ratio of histologically reviewed prior melanomas to borderline lesions
is 4.8; the ratio of prospective melanomas to borderline lesions is 1.6.
The average age at first borderline lesion was 28 years (range 3–54)
and did not differ in the two time periods.
One-thousand six-hundred-one nevi from 254 family members
have been histologically reviewed. The average number of nevi
removed per family member is six (range 1–90). In the beginning of the
study, each family member and spouse was asked to have the most
atypical nevus removed. Sixteen spouses, four of whom had clinically
dysplastic nevi, and 73 family members with normal skin examina-
tions underwent biopsy of their most atypical nevus. None of the
clinically normal relatives or clinically normal spouses had histologic
evidence of dysplastic nevi. Routine biopsy of clinically banal nevi
was therefore abandoned. The nevi of the four spouses with clinically
dysplastic nevi showed histologic dysplasia also. The age at first
clinical and histologic evidence of dysplastic nevi ranged from 3 to
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67 years but averaged 32. This age does not reflect age at onset of
dysplastic nevi but rather age at first examination.
The cumulative risk of developing melanoma between ages 10 and
50 years among participants with dysplastic nevi was 48.9±4.2% and
rose to 81.6%±6.7% by age 72 years (Fig 1). Ten of the participants
with melanoma developed their first melanoma before age 20 years.
The prospective risk of melanoma in participants with dysplastic nevi
or previous melanoma under age 20 years was 1950 times increased
(95% confidence interval 397–5693).
All of the prospective melanomas occurred in participants with
dysplastic nevi. The prospective risk of melanoma was increased 229
times in those who had previous melanoma (Table II) and increased 85
times in those with dysplastic nevi. The risk of melanoma in family
members with dysplastic nevi was approximately 10 times the risk of a
subsequent melanoma among people with melanoma in the Connecti-
cut Tumor Registry. With more prolonged follow-up, the relative risks
of prospective melanomas overall in family members with previous
melanoma or dysplastic nevi are somewhat lower than originally
reported [12]. The risks were highest in the first 5 years and decreased
after 5 years of follow-up. These decreases were present in family
members with melanoma and dysplastic nevi and also in the people in
the Connecticut Tumor Registry. The changes were most marked in the
relative risks but were also seen in the excess risks. The change in the
excess risk of the family members with dysplastic nevi was much
smaller than the change in those with melanoma, partly because the
family members with dysplastic nevi entered an age when the risk
of melanoma was much higher, as reflected in the increase in the
expected values. Including the 46 index cases in the analyses or using
the Surveillance, Epidemiology, and End Results rates or omitting the
few melanomas that occurred in the first year did not change the
overall risks or the time-specific risks substantively.
If the family members with dysplastic nevi and/or melanoma are
combined, in the first 5 years (617.8 person-years), 12 developed 24
melanomas compared with 0.06 expected [relative risk 197; 95%
confidence interval 102–344]. In that same time interval, 13people
developed 19 borderline lesions (four of whom also developed
melanoma in the same time interval). In the subsequent follow-up
(614.6 person-years), seven people developed 23 melanomas,
compared with 0.08 expected (relative risk 87; 95% confidence
interval 35–183). Six developed 11 borderline lesions (one of whom
also developed melanoma in the same time period). Thus, the pattern
of developing borderline lesions closely resembled the pattern of
developing melanomas in this group. Both decreased after 5 years
of followup. During the later period, the rate of nevus excisions in
family members with dysplastic nevi or melanoma also decreased
from 0.9/person-year during the first 5 years of study participation to
0.4/person-year.
Of the 79 participants alive at the beginning of the study who have
developed melanoma, 33 (42%) have had multiple primary melano-
mas. The risk of developing subsequent melanomas appears to
increase with the number of previous melanomas (Table III). Data
for all time periods (retrospective plus prospective) are shown as well
as data for the prospective melanomas because of the very small
numbers in the prospective time period. The trends in risk for the
subsequent primary melanomas were significant for all time periods
(p¼ 0.02) but did not reach statistical significance for the prospective
time period only. Again, including the index cases had little effect on
the risks. Eleven of the 46 family members with single primary
melanomas alive at the time of the family’s entry into the study have
died: eight of melanoma, one of lung cancer, one of esophageal
cancer, and one because of an accident. Ten of the 33 family members
with multiple melanomas have died: six of melanoma, one of kidney
Table I. Characteristics of Previous and Prospective







Superficial spreading 114 (83) 44 (94)
Nodular 12 (8.8) 3 (6)
Unclassified 9 (6.6)
Acral lentiginous 1 (0.7)
Lentigo maligna 1 (0.7)
Precursor lesion
Dysplastic nevus 72 (53) 29 (63)
Nevus, not dysplastic 17 (12) 5 (11)
None 38 (28) 10 (22)
Unknown 10 (7) 2 (4)
Thickness
Not measured 21 (16) 19 (42)
o0.76mm 55 (43) 20 (44)
0.76–1.5mm 32 (25) 4 (9)
41.5mm 20 (16) 2 (4)
Clark level
Microinvasive 20 (14) 19 (41)
II 53 (38) 16 (35)
III 45 (33) 6 (13)
IV 15(11) 4 (9)
V 0 0
Unknown 5 (4) 1 (2)
Figure 1. Cumulative actuarial probability of developing cutaneous
melanoma as a function of age among family members with dysplastic nevi.
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cancer, one of lung cancer, one of complications following surgery for
a meningioma, and one because of an accident. Twenty-five of the 26
family members who were dead at the time of their family’s entry into
the study had single primary melanomas; one had multiple primaries.
The prospective risk of cancers other than melanoma was
evaluated among all the bloodline relatives (Table IV). Other cancers
were considered by organ system rather than individual site because of
the relatively small numbers. Overall, there was an excess of all
cancers, but this was due to the excess of melanomas. There was no
significant increase in other cancers. If a putative gene for melanoma
and dysplastic nevi caused a generalized tumor diathesis, those with
melanoma and/or dysplastic nevi would be most likely to demonstrate
an excess risk of other cancers. In this group, however, most of the
excess risk was due to melanoma. Although all gastrointestinal cancers
combined demonstrated a significant excess, this was not due to a
single site and may have occurred by chance alone. The three cancers
that occurred were in the esophagus, colon, and pancreas in members
of three different families.
DISCUSSION
This report refines and extends previously published findings [12]. The
excess risk of melanoma in the families studied remains restricted to
those participants with prior melanoma or dysplastic nevi. No excess
of other cancers is associated with the presence of dysplastic nevi and
melanoma in these families.
The cumulative risk of melanoma by age 50 years in people with
dysplastic nevi is 48%±4.2%. It is important to note that this risk starts
early, at approximately age 10 years. In these families, 10% of
melanoma cases developed melanoma before age 20 years, compared
with 2% of melanoma cases in the general population [23]. The
difference is most striking under age 15 years, when 4% of family
members with melanoma develop the first melanoma, compared with
0.4% of the general population. The relative risk in family members
under age 20 years with dysplastic nevi is extremely elevated. This
finding has vital implications for the clinical evaluation of these
families. In the past, we have generally advocated intermittent
examinations of children until puberty, when dysplastic nevi tend to
Table II. Prospective Risk of Melanoma in Family Member Groups and in Connecticut Tumor Registrya
Person-Years Obs Exp Obs/Exp (95% CI) Excess Risk
Total time period
Previous melanoma 259 10 0.044 229 (110–422) 384
Dysplastic nevi, no previous melanoma 1,104 10 0.118 85 (41–156) 90
Normal relatives 1,591 0 0.177 0 (0–21) 0
Connecticut Tumor Registry, prior melanoma 27,815 30 3.51 8.5 (5.8–12.2) 9.5
o5-Year follow-up
Previous melanoma 137 7 0.019 362 (147–759) 510
Dysplastic nevi, no previous melanoma 501 5 0.039 127 (41–299) 99
Connecticut Tumor Registry, prior melanoma 14,656 19 1.74 11 (6.6–17.1) 12
45-Years follow-up
Previous melanoma 122 3 0.025 120 (24–351) 243
Dysplastic nevi, no previous melanoma 603 5 0.079 63 (20–148) 82
Connecticut Tumor Registry, prior melanoma 13,159 11 1.77 6.2 (3.1–11.1) 7
aObs, observed; Exp, expected; CI, confidence interval.
Table III. Risk of Subsequent Melanomas Among Family Members with at Least One Melanomaa
Person-Years Obs Exp Obs/Exp (95% CI) Excess Risk
All time periods
Second melanoma 424 16 0.057 281 (161–457) 376
Third melanoma 62 7 0.008 929 (372–1915) 1128
Fourth melanoma 32 4 0.006 704 (189–1801) 1248
Prospective only
Second melanoma 72 5 0.009 533 (171–1244) 693
Third melanoma 19 3 0.002 1464 (294–4278) 1578
aObs, observed; Exp, expected; CI, confidence interval.
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become more evident [26,27]. These current data suggest that routine
screening should start at age 10 years or before.
Careful follow-up of these family members had led to a substantial
decrease in the thickness of melanomas over time. The only
melanomas greater than 0.76mm thick occurred in family members
who had not followed the skin-care guidelines and who had not
had routine skin examinations. The decrease in thickness of the
melanomas and the decreasing ratio of melanomas to borderline
lesions in the prospective follow-up indicate that the lesions are being
removed at a biologically earlier stage when they pose less risk to the
subject. The majority of the prospective lesions are radial growth
phase only, which have no potential for metastasis [28]. Over time,
this should lead to a substantial decrease in mortality from melanoma
in these families. The increase in the percentage of people with
multiple primary melanomas over time may also reflect the earlier
diagnosis of those lesions. In the earlier time period, prior to the
initiation of the study, a higher percentage of the patients died of their
first melanoma, before they had an opportunity to develop multiple
primary lesions. In comparison to the Connecticut Tumor Registry
data, members of these families with previous melanoma are many
times more likely to develop a second melanoma. Those with
dysplastic nevi are approximately 10 times as likely to develop a
melanoma than those with previous melanoma in the Connecticut
data, who are also at high risk of developing a subsequent melanoma.
In these families, not all members develop multiple melanomas.
Among those who do, the risk of successive melanomas continues to
increase.
Although the risks for subsequent melanomas among people with
melanoma are still extremely high, they are somewhat lower than
previously reported. The earlier estimates were based essentially on
the first 5 years of follow-up. Within the same time period in this
expanded data set, the risks are similar. The overall decrease is
attributable to a decrease in the risk of subsequent melanomas after 5
years. There are several possible explanations for the decrease. The
first could be that surveillance and early biopsy of lesions remove
possible melanomas before they become invasive. The decrease in the
ratio of melanomas to borderline lesions would indicate that this may
play some part. A second might be that we have incomplete follow-up
information about subsequent melanomas and that melanomas are
actually occurring at the same rate. This is unlikely, given the number
of contacts we have with various family members and the frequency of
notification of nevus excisions we receive from family members.
Another explanation is that the family members may be changing their
behavior, so that the rate of nevus progression, and therefore
melanoma development, may be altered. The patterns of decreasing
nevus excisions, decreasing new melanoma cases, and decreasing
borderline cases are consistent with this hypothesis. In a recent
questionnaire survey of the family members, all of those with
melanoma indicated that they had changed their sun habits since
entering the study (M. A. Tucker, unpublished data). Most stated that
they had changed their habits at time of initial evaluation. If this were
true, then the 5 years might be an indication of the duration of sun
effect on the progression of the nevi. Chance occurrence could also
explain the decrease, but this seems less likely given the consistency in
the patterns of nevi, borderline lesions, and melanomas.
Although these data clearly indicate that clinical evaluation and
thorough follow-up of these family members can lead to earlier
diagnosis of melanoma in a very high-risk group, the same level of
scrutiny may not be feasible or cost-effective in the general
population. Approximately 10% of melanomas have been estimated
to occur in people having a first-degree relative with melanoma.
Although up to half of all melanomas may occur in people with
dysplastic nevi [29], the level of risk of melanoma in people with
dysplastic nevi who are not members of melanoma-prone families has
not yet been firmly established and is under active investigation. Until
more data are available, it is premature to extrapolate the level of care
that we have advocated for melanoma-prone family members to
people with dysplastic nevi who do not have a family member with
melanoma. Data are now emerging, however, that indicate that
regular follow-up of people with dysplastic nevi, regardless of family
history, can lead to early diagnosis of melanoma [30]. With the data
from current studies of the risk of melanoma associated with dysplastic
nevi, a better estimate of care guidelines for specific risk groups may
be possible.
Table IV. Prospective Risk of Other Cancers in Family Member Groupsa
All bloodline (person-years 5301.6) DN/Melanoma (person-years 1232.3)
Tumor type Obs Exp Obs/Exp (95% CI) Obs Exp Obs/Exp (95% CI)
All cancers 35 20.6 1.7 (1.2–2.4) 23 2.9 7.8 (4.9–11.7)
Buccal cavity/pharynx 0 0.6 0 0.1
Digestive system 4 5.2 0.8 (0.2–2.0) 3 0.5 5.6 (1.1–16.3)
Respiratory system 4 3.4 1.2 (0.3–3.1) 0 0.5
Female breast 3 3.0 1.0 (0.2–2.9) 0 0.5
Female genital tract 0 1.4 0 0.2
Male genital tract 0 1.7 0 0.2
Kidney 0 0.5 0 0.1
Urinary bladder 1 1.1 0.9 (0.0–5.1) 0 0.1
Melanoma 19 0.6 32 (19–50) 19 0.1 132 (79–206)
Eye, brain, and CNS 0 0.4 0 0.1
Endocrine glands 0 0.2 0 0.1
Bone/connective tissue 0 0.1 0 0.0
Lymphatic/hematopoietic 3 1.6 1.8 (0.4–5.4) 1 0.3 4.0 (0.0–22)
aDN, dysplastic nevi; Obs, observed; Exp, expected; CI, confidence interval; CNS, central nervous system.
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